Published:29/12/2020
Vectura Group plc (LSE: VEC) (“Vectura”), an industry-leading specialist inhalation CDMO, today confirms that GlaxoSmithKline (GSK) has not sought to petition the US Court of Appeals for a re-hearing in our ongoing Ellipta® litigation. Accordingly, the Court of Appeals has issued the Mandate to the United States District Court for the District of Delaware and Vectura expects GSK to make payment of the current award plus interest by late January 2021. The specific amount of the award will be confirmed in due course.
You can read the full announcement here.